SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : DOSE(capstone pharm) -- Ignore unavailable to you. Want to Upgrade?


To: LLCF who wrote (43)7/27/1998 10:26:00 PM
From: Rob Anderson  Read Replies (1) | Respond to of 92
 
DOSE is a screaming buy at this price.

I believe the street overeacted to the earnings short fall of First Call estimate.

*Price to sales .97
*Book value $6.17
*Trading below book value
*PE less than 11 Sector I believe is 18
*Priced in relation to sector PE 18 * .56 = $10.08 per share
*Short fall of earnings estimate seems to be related to acquisitions
*One of the leaders in sector
*Growth thru acquisition